PMID- 31524258
OWN - NLM
STAT- MEDLINE
DCOM- 20200204
LR  - 20200225
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 20
IP  - 3
DP  - 2019 Sep
TI  - 1,25‑Dihydroxyvitamin D3 enhances the susceptibility of anaplastic thyroid cancer 
      cells to adriamycin‑induced apoptosis by increasing the generation of reactive 
      oxygen species.
PG  - 2641-2648
LID - 10.3892/mmr.2019.10530 [doi]
AB  - Anaplastic thyroid cancer (ATC) is a very aggressive malignancy that is resistant 
      to various types of chemotherapy in humans. Most patients with late‑stage ATC 
      cannot undergo surgery and receive chemotherapy drugs. The present study 
      investigated the influence of 1,25‑dihydroxyvitamin D3 (1,25(OH)2D3) pretreatment 
      on adriamycin (ADM) chemotherapy efficacy in the 8305c and 8505c ATC cell lines. 
      The apoptotic effects of ADM on ATC cells pretreated with 1,25(OH)2D3 were 
      evaluated. Cell viability was identified by using the Cell Counting Kit‑8 assay. 
      Apoptosis was assessed by flow cytometry and staining with Hoechst 33342. The 
      expression of the apoptotic protein cleaved caspase‑3 was tested with a 
      colorimetric assay kit and by western blotting. Reactive oxygen species (ROS) 
      generation was assessed with the antioxidant N‑acetyl‑L‑cysteine (NAC) and the 
      assay H2‑DCFDA. In addition, ROS production could be reversed by NAC treatment. 
      The present study demonstrated that 1,25(OH)2D3 enhanced ADM‑induced apoptosis in 
      8305c and 8505c cell lines. Furthermore, 1,25(OH)2D3 improved the ADM‑induced ROS 
      production and expression of cleaved caspase‑3. NAC treatment inhibited the 
      expression of cleaved caspase‑3 in ATC cells, and reduced apoptosis in cells that 
      were pretreated with 1,25(OH)2D3 and ADM. These results demonstrated that 
      1,25(OH)2D3 may enhance ADM‑induced apoptosis by increasing ROS generation in ATC 
      cells.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Thyroid Surgery, The First Hospital of China Medical University, 
      Shenyang, Liaoning 110001, P.R. China.
FAU - He, Liang
AU  - He L
AD  - Department of Thyroid Surgery, The First Hospital of China Medical University, 
      Shenyang, Liaoning 110001, P.R. China.
FAU - Sun, Wei
AU  - Sun W
AD  - Department of Thyroid Surgery, The First Hospital of China Medical University, 
      Shenyang, Liaoning 110001, P.R. China.
FAU - Qin, Yuan
AU  - Qin Y
AD  - Department of Thyroid Surgery, The First Hospital of China Medical University, 
      Shenyang, Liaoning 110001, P.R. China.
FAU - Zhang, Ping
AU  - Zhang P
AD  - Department of Thyroid Surgery, The First Hospital of China Medical University, 
      Shenyang, Liaoning 110001, P.R. China.
FAU - Zhang, Hao
AU  - Zhang H
AD  - Department of Thyroid Surgery, The First Hospital of China Medical University, 
      Shenyang, Liaoning 110001, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190725
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Biomarkers)
RN  - 0 (Reactive Oxygen Species)
RN  - 80168379AG (Doxorubicin)
RN  - EC 3.4.22.- (CASP3 protein, human)
RN  - EC 3.4.22.- (Caspase 3)
RN  - FXC9231JVH (Calcitriol)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Biomarkers
MH  - Calcitriol/*pharmacology
MH  - Caspase 3/metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Doxorubicin/*pharmacology
MH  - Enzyme Activation/drug effects
MH  - Humans
MH  - Reactive Oxygen Species/*metabolism
MH  - Thyroid Carcinoma, Anaplastic/*etiology/*metabolism/pathology
PMC - PMC6691249
EDAT- 2019/09/17 06:00
MHDA- 2020/02/06 06:00
PMCR- 2019/07/25
CRDT- 2019/09/17 06:00
PHST- 2018/11/10 00:00 [received]
PHST- 2019/06/05 00:00 [accepted]
PHST- 2019/09/17 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2019/09/17 06:00 [entrez]
PHST- 2019/07/25 00:00 [pmc-release]
AID - mmr-20-03-2641 [pii]
AID - 10.3892/mmr.2019.10530 [doi]
PST - ppublish
SO  - Mol Med Rep. 2019 Sep;20(3):2641-2648. doi: 10.3892/mmr.2019.10530. Epub 2019 Jul 
      25.